MDoloris Announces Development of the World’s 1s Closed Loop Peri-operative Analgesia System

MDoloris is proud to announce that it has reached a major new milestone in the control of peri-operative nociception, in close collaboration with Lille University Hospital and with the support of SATT Nord.

The culmination of almost 20 years of R&D and commercial development through the start-up MDoloris, the creation of an automated system for regulating perioperative pain based on continuous optimization of para-sympathetic tone is a world first.

Closed-loop control systems are still rare in anesthesia today, but they provide greater reliability in achieving set objectives, reduce the risk of human error and free the anesthesiologist from the burden of manually adapting the administration of the various therapies required for surgery 1,2.

Today, the administration of certain drugs is carried out by concentration-targeted perfusion systems controlled by the anesthetist. In theory, these systems maintain a constant concentration of active ingredient in the brain tissue, according to targets set continuously by the anesthesiologist, who remains involved by constantly adapting concentrations to the patient’s intra-operative needs.

The MDoloris closed-loop control system uses direct measurements of the effect of drugs on the patient’s autonomic nervous system – in this case, the measurement of para-sympathetic tone thanks to MDoloris technology – to constantly optimize morphine administration to the patient’s needs.

The continuously measured state provides feedback for subsequent dose control. This enables the anesthesiologist to concentrate on other essential tasks during surgery, such as monitoring vital physiological signals, dealing with blood loss, any anti-infectious therapies or modifying the infusion doses of other drugs used2.

In practice, the proprietary algorithm developed by MDoloris is based on analysis of changes in the ANI index and blood pressure, and enables to continuously personalize morphine administration during general anesthesia according to patients’ instantaneous needs.

This sentinel system detects the pain phenomenon induced by the surgical procedure and automatically administers the right dose of treatment at the right time, and for the necessary and sufficient duration.

Considering that the quality of anesthesia influences the therapeutic success of surgery, it’s easy to appreciate the importance of this technological advance3.

Dr. Matthieu Jeanne, Ph.D., Chief of Anesthesia and Intensive Care, Burn Treatment Center, principal investigator of the prospective randomized clinical validation study said, “This world first is an important step forward for the practice of anesthesia in general. This closed loop is the best companion for the surgeon, the anesthetist, and the patient since all three can be assured that the operation will be carried out in the best conditions of patient comfort and pain control”.

Fabien Pagniez Founder and CEO of MDoloris stated, “MDoloris is particularly proud to be associated with this discovery, which further strengthens its role as a pioneer and leader in the measurement of pain in anesthesia. Through its proprietary ANI index, this biological parameter, which represents the activity of the parasympathetic nervous system and enables, among other things, the measurement of nociception induced by surgery, is now expressing its full therapeutic potential through the development of this closed-loop system. Clinical validation of MDoloris closed-loop technology promises a quantum leap in patient benefit, not only during surgery, but also in the post-operative phase and beyond. The simplification of personalized anesthesia is underway, and the Medicine of the Future is now a reality.’’

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version